Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Sep;65(9):3520–3528. doi: 10.1128/iai.65.9.3520-3528.1997

Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1.

S Sasaki 1, T Tsuji 1, K Hamajima 1, J Fukushima 1, N Ishii 1, T Kaneko 1, K Q Xin 1, H Mohri 1, I Aoki 1, T Okubo 1, K Nishioka 1, K Okuda 1
PMCID: PMC175502  PMID: 9284115

Abstract

To enhance immunity induced by DNA vaccination against human immunodeficiency virus type 1 (HIV-1), we evaluated the efficacy of monophosphoryl lipid A (MPL), an adjuvant of bacterial origin. BALB/c mice were intramuscularly injected with immunogenic DNA, encoding the env and rev genes of the HIV-1(IIIB) strain, formulated with MPL dissolved in different vehicles (MPL in stable emulsion and MPL in aqueous formulation). The sera from mice immunized with the two preparations of MPL revealed 2(6) to 2(9) times higher HIV-1-specific immunoglobulin G (IgG) titers than the sera from mice immunized without MPL. In virus neutralization tests for HIV-1(IIIB), by p24 assay and antifusion assay of infected MOLT-4 cells, MPL tends to elicit antibody more protective than antibody elicited without adjuvant. MPL also elicited stronger delayed-type hypersensitivity and cytotoxic-T-lymphocyte activity against HIV-1(IIIB) compared to DNA alone. HIV-1-specific IgG subclass analysis showed that MPL tends to facilitate IgG2a production, suggesting enhancement of a predominant T-helper-type-1 response, and this enhancement may help to facilitate protective-antibody induction. Furthermore, a chloramphenicol acetyltransferase (CAT) assay was employed to determine whether MPL affected the gene expression process. Interestingly, both MPL preparations reduced CAT activity in the muscle injected with CAT expression vector but increased anti-CAT antibody production. These results indicate that MPL acts as an effective adjuvant for immunogenic DNA injection despite reduced expression of encoding protein in muscle. We conclude that MPL has a strong adjuvant effect on DNA vaccination against HIV-1.

Full Text

The Full Text of this article is available as a PDF (287.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benoit P. W., Belt W. D. Destruction and regeneration of skeletal muscle after treatment with a local anaesthetic, bupivacaine (Marcaine). J Anat. 1970 Nov;107(Pt 3):547–556. [PMC free article] [PubMed] [Google Scholar]
  2. Bukawa H., Sekigawa K., Hamajima K., Fukushima J., Yamada Y., Kiyono H., Okuda K. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat Med. 1995 Jul;1(7):681–685. doi: 10.1038/nm0795-681. [DOI] [PubMed] [Google Scholar]
  3. Carozzi S., Salit M., Cantaluppi A., Nasini M. G., Barocci S., Cantarella S., Lamperi S. Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol. 1989 Aug;27(8):1748–1753. doi: 10.1128/jcm.27.8.1748-1753.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Corr M., Lee D. J., Carson D. A., Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med. 1996 Oct 1;184(4):1555–1560. doi: 10.1084/jem.184.4.1555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cullen B. R. Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell. 1986 Sep 26;46(7):973–982. doi: 10.1016/0092-8674(86)90696-3. [DOI] [PubMed] [Google Scholar]
  6. Daniel M. D., Kirchhoff F., Czajak S. C., Sehgal P. K., Desrosiers R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. doi: 10.1126/science.1470917. [DOI] [PubMed] [Google Scholar]
  7. Davis H. L., Michel M. L., Whalen R. G. Use of plasmid DNA for direct gene transfer and immunization. Ann N Y Acad Sci. 1995 Nov 27;772:21–29. doi: 10.1111/j.1749-6632.1995.tb44728.x. [DOI] [PubMed] [Google Scholar]
  8. Gustafson G. L., Rhodes M. J. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol. 1992 Jun;143(5):483–574. doi: 10.1016/0923-2494(92)80058-s. [DOI] [PubMed] [Google Scholar]
  9. Hahn Y. S., Hahn C. S., Braciale V. L., Braciale T. J., Rice C. M. CD8+ T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J Exp Med. 1992 Nov 1;176(5):1335–1341. doi: 10.1084/jem.176.5.1335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hassett D. E., Whitton J. L. DNA immunization. Trends Microbiol. 1996 Aug;4(8):307–312. doi: 10.1016/0966-842x(96)10048-2. [DOI] [PubMed] [Google Scholar]
  11. Ishizaka S. T., Piacente P., Silva J., Mishkin E. M. IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J Infect Dis. 1995 Oct;172(4):1108–1111. doi: 10.1093/infdis/172.4.1108. [DOI] [PubMed] [Google Scholar]
  12. Keefer M. C., Graham B. S., McElrath M. J., Matthews T. J., Stablein D. M., Corey L., Wright P. F., Lawrence D., Fast P. E., Weinhold K. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1996 May 20;12(8):683–693. doi: 10.1089/aid.1996.12.683. [DOI] [PubMed] [Google Scholar]
  13. Kumar V., Sercarz E. Genetic vaccination: the advantages of going naked. Nat Med. 1996 Aug;2(8):857–859. doi: 10.1038/nm0896-857. [DOI] [PubMed] [Google Scholar]
  14. Layton G. T., Harris S. J., Gearing A. J., Hill-Perkins M., Cole J. S., Griffiths J. C., Burns N. R., Kingsman A. J., Adams S. E. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J Immunol. 1993 Jul 15;151(2):1097–1107. [PubMed] [Google Scholar]
  15. Lu S., Santoro J. C., Fuller D. H., Haynes J. R., Robinson H. L. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology. 1995 May 10;209(1):147–154. doi: 10.1006/viro.1995.1238. [DOI] [PubMed] [Google Scholar]
  16. Malim M. H., Hauber J., Fenrick R., Cullen B. R. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature. 1988 Sep 8;335(6186):181–183. doi: 10.1038/335181a0. [DOI] [PubMed] [Google Scholar]
  17. Mor G., Singla M., Steinberg A. D., Hoffman S. L., Okuda K., Klinman D. M. Do DNA vaccines induce autoimmune disease? Hum Gene Ther. 1997 Feb 10;8(3):293–300. doi: 10.1089/hum.1997.8.3-293. [DOI] [PubMed] [Google Scholar]
  18. Mosmann T. R., Cherwinski H., Bond M. W., Giedlin M. A., Coffman R. L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986 Apr 1;136(7):2348–2357. [PubMed] [Google Scholar]
  19. Newman M. J., Munroe K. J., Anderson C. A., Murphy C. I., Panicali D. L., Seals J. R., Wu J. Y., Wyand M. S., Kensil C. R. Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant. AIDS Res Hum Retroviruses. 1994 Jul;10(7):853–861. doi: 10.1089/aid.1994.10.853. [DOI] [PubMed] [Google Scholar]
  20. Okuda K., Bukawa H., Hamajima K., Kawamoto S., Sekigawa K., Yamada Y., Tanaka S., Ishi N., Aoki I., Nakamura M. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res Hum Retroviruses. 1995 Aug;11(8):933–943. doi: 10.1089/aid.1995.11.933. [DOI] [PubMed] [Google Scholar]
  21. Okuda K., Bukawa H., Kawamoto S., Imai M., Saito T., Phanuphak P., Hamajima K. A serologic analysis and the amino acid sequence of the V3 region of human immunodeficiency virus from carriers in Bangkok. J Infect Dis. 1994 Jan;169(1):227–228. doi: 10.1093/infdis/169.1.227. [DOI] [PubMed] [Google Scholar]
  22. Okuda K., Ishii N., Ikezawa Z., Takahashi T., Arai K., Tadokoro I. Delayed-type hypersensitivity to hen egg-white lysozyme. I. The surface phenotypes of suppressor T cells induced by intravenous injection of lysozyme-modified spleen cells, and their molecular interactions. Microbiol Immunol. 1982;26(10):897–911. doi: 10.1111/j.1348-0421.1982.tb00236.x. [DOI] [PubMed] [Google Scholar]
  23. Powell M. F., Eastman D. J., Lim A., Lucas C., Peterson M., Vennari J., Weissburg R. P., Wrin T., Kensil C. R., Newman M. J. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs. AIDS Res Hum Retroviruses. 1995 Feb;11(2):203–209. doi: 10.1089/aid.1995.11.203. [DOI] [PubMed] [Google Scholar]
  24. Putney S. D., Matthews T. J., Robey W. G., Lynn D. L., Robert-Guroff M., Mueller W. T., Langlois A. J., Ghrayeb J., Petteway S. R., Jr, Weinhold K. J. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science. 1986 Dec 12;234(4782):1392–1395. doi: 10.1126/science.2431482. [DOI] [PubMed] [Google Scholar]
  25. Rickman L. S., Gordon D. M., Wistar R., Jr, Krzych U., Gross M., Hollingdale M. R., Egan J. E., Chulay J. D., Hoffman S. L. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 1991 Apr 27;337(8748):998–1001. doi: 10.1016/0140-6736(91)92659-p. [DOI] [PubMed] [Google Scholar]
  26. Robinson H. L., Lu S., Mustafa F., Johnson E., Santoro J. C., Arthos J., Winsink J., Mullins J. I., Montefiori D., Yasutomi Y. Simian immunodeficiency virus DNA vaccine trial in macaques. Ann N Y Acad Sci. 1995 Nov 27;772:209–211. doi: 10.1111/j.1749-6632.1995.tb44746.x. [DOI] [PubMed] [Google Scholar]
  27. Schneerson R., Fattom A., Szu S. C., Bryla D., Ulrich J. T., Rudbach J. A., Schiffman G., Robbins J. B. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. J Immunol. 1991 Oct 1;147(7):2136–2140. [PubMed] [Google Scholar]
  28. Takahashi H., Germain R. N., Moss B., Berzofsky J. A. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself. J Exp Med. 1990 Feb 1;171(2):571–576. doi: 10.1084/jem.171.2.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ulmer J. B., Deck R. R., Dewitt C. M., Donnhly J. I., Liu M. A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology. 1996 Sep;89(1):59–67. doi: 10.1046/j.1365-2567.1996.d01-718.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., DeWitt C. M., Friedman A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993 Mar 19;259(5102):1745–1749. doi: 10.1126/science.8456302. [DOI] [PubMed] [Google Scholar]
  31. Ulrich J. T., Myers K. R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol. 1995;6:495–524. [PubMed] [Google Scholar]
  32. Vilquin J. T., Guérette B., Kinoshita I., Roy B., Goulet M., Gravel C., Roy R., Tremblay J. P. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther. 1995 Nov;6(11):1391–1401. doi: 10.1089/hum.1995.6.11-1391. [DOI] [PubMed] [Google Scholar]
  33. Vitadello M., Schiaffino M. V., Picard A., Scarpa M., Schiaffino S. Gene transfer in regenerating muscle. Hum Gene Ther. 1994 Jan;5(1):11–18. doi: 10.1089/hum.1994.5.1-11. [DOI] [PubMed] [Google Scholar]
  34. Vogel F. R. The role of adjuvants in retroviral vaccines. Int J Immunopharmacol. 1995 Feb;17(2):85–90. doi: 10.1016/0192-0561(94)00095-6. [DOI] [PubMed] [Google Scholar]
  35. Wechsler D. S., Kongshavn P. A. Heat-labile IgG2a antibodies affect cure of Trypanosoma musculi infection in C57BL/6 mice. J Immunol. 1986 Nov 1;137(9):2968–2972. [PubMed] [Google Scholar]
  36. Wells D. J. Improved gene transfer by direct plasmid injection associated with regeneration in mouse skeletal muscle. FEBS Lett. 1993 Oct 11;332(1-2):179–182. doi: 10.1016/0014-5793(93)80508-r. [DOI] [PubMed] [Google Scholar]
  37. Xiang Z., Ertl H. C. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity. 1995 Feb;2(2):129–135. doi: 10.1016/s1074-7613(95)80001-8. [DOI] [PubMed] [Google Scholar]
  38. Zhou F., Huang L. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccine. 1993;11(11):1139–1144. doi: 10.1016/0264-410x(93)90076-a. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES